Cded in remission patients with high calprotectin

Due to the success of diet in achieving remission in mild-moderate forms of the disease, and an increasing number of patients with loss of response to available drugs despite increasing dose and pathophysiology of the disease, the aim of the present study is to evaluate whether there is response with the addition of diet therapy in patients with moderate/severe forms of CD receiving biologic therapy (infliximab or adalimumab) and presenting active disease.

Inclusion Criteria:

• Patients under 18 years of age
• With a diagnosis of CD
• Who have completed remission induction with biologic therapy
• Who are on maintenance biologic therapy
• Present calprotectin values higher than the limit values established by the laboratory (higher than 250 ug/g).

Exclusion Criteria:

• Children who are unable to receive enteral dietary intake
• Comorbidities affecting nutritional status and/or bone metabolism, growth or pubertal development
• Children already on special diets